#United States #New York #class action lawsuit #Pomerantz Law Firm #INOVIO Pharmaceuticals

Pomerantz Law Firm Initiates Class Action Against Inovio Pharmaceuticals

In the latest legal development concerning biotechnology firms, the Pomerantz Law Firm has declared the initiation of a class action lawsuit against Inovio Pharmaceuticals, Inc., and several of its top executives. Filed in the United States District Court for the Eastern District of Pennsylvania, this lawsuit is expected to address potential violations of federal securities laws affecting investors who acquired Inovio securities from October 10, 2023, to December 26, 2025.

The class action underscores claims that the defendants engaged in misleading practices which ultimately affected the valuation and performance of Inovio's shares during the class period. Inovio, a company known for its innovative approach to DNA medicines aimed at combating human papillomavirus (HPV) among other diseases, previously attracted considerable investor interest due to its anticipated FDA approvals for its lead product candidate, INO-3107.

Legal Framework and Investor Impact

The lawsuit filed by Pomerantz LLP is centered on allegations that Inovio and its officers violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as well as Rule 10b-5. These violations are purportedly connected to the company's misleading public statements regarding its product development and regulatory prospects. Investors impacted by the alleged misrepresentations are encouraged to seek appointment as Lead Plaintiffs by the approaching deadline of April 7, 2026.

The centerpiece of Inovio's product offerings is INO-3107, which has been positioned as a promising treatment option for recurrent respiratory papillomatosis (RRP), a rare condition attributed to HPV infection. Throughout the class period, Inovio executives reportedly promoted optimistic timelines for FDA submissions for INO-3107, thereby fostering investor confidence and inflating stock values in the process.

However, it has come to light that production issues with the CELLECTRA device, integral to the delivery of INO-3107, could hinder the company's FDA submission timeline, pushing it back to mid-2025. This revelation marked a pivotal moment in the class action narrative.

Market Reactions and Share Performance

The implications of the unfolding situation were evident as market reactions reflected a loss of investor confidence following significant announcements by Inovio. Shares plummeted on August 9, 2024, when the company disclosed the anticipated delay due to manufacturing deficiencies, leading to a notable dip of 3.1% in stock value.

Adding to the unease among shareholders, further disclosures made on December 29, 2025, revealed that the FDA had accepted the INO-3107 Biologics License Application (BLA) for review under standard procedures rather than the expedited route that had been publicly asserted by company executives. This news resulted in an alarming 24.45% drop in the share price, signaling a major shakeup in investor sentiment.

Pomerantz's Legacy in Securities Litigation

The Pomerantz Law Firm's involvement in this class action continues its longstanding tradition of advocacy for investor rights. Founded by Abraham L. Pomerantz, known as a pioneer in the field of securities class actions, the firm has garnered a reputation for effectively tackling corporate fraud and misconduct issues.

Throughout its 85-year history, Pomerantz has aggressively championed the cause of investors, recovering billions of dollars for those wronged by corporate actions and ensuring that such entities are held accountable for their misdeeds. The outcomes of this particular case remain to be seen, but it exemplifies the firm’s commitment to protecting the interests of the investing public.

How to Get Involved

For investors who acquired Inovio securities during the specified period, this class action presents an opportunity for recovery of losses that may have stemmed from the alleged corporate misconduct. Interested parties are encouraged to reach out to the firm’s legal representatives to discuss potential involvement in the class action.

As the legal proceedings unfold, the case serves as an important reminder of the necessity for transparency and integrity in corporate communications, particularly in the biotechnology sector which often operates under high expectations and pressures from investors.

For further information or to specifically join the class action, please visit the Pomerantz website or contact them directly. This unfolding legal saga will undoubtedly impact the future trajectory of Inovio Pharmaceuticals significantly.